European perspective on human polyomavirus infection, replication and disease in solid organ transplantation

Clinical Microbiology and Infection

Volumn 20, Issue s7, 2014, Pages 74-88

  Hirsch, H H ^a,b   Babel, N ^c   Comoli, P ^d   Friman, V ^e   Ginevri, F ^f   Jardine, A ^g   Lautenschlager, I ^h   Legendre, C ⁱ   Midtvedt, K ^j   Munoz P ^k,l   Randhawa, P ^m   Rinaldo, C H ^n,o   Wieszek, A ^p  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f G GASLINI INSTITUTE   (Italy)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^l UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^m UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁿ UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^o UNIVERSITY OF TROMSØ   (Norway)

^p MEDICAL UNIVERSITY OF SILESIA   (Poland)

more..

Author keywords

Merkel cell carcinoma; Nephropathy; Polyoma; Progressive multifocal leukoencephalopathy; PyVAN; Solid organ transplantation; Trichodysplasia spinulosa; Virus

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CIPROFLOXACIN; CYCLOSPORIN A; IMMUNOGLOBULIN; INSULIN; LEFLUNOMIDE; LEVOFLOXACIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEFLOQUINE; MIRTAZAPINE; MYCOPHENOLIC ACID; NATALIZUMAB; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ANTIVIRAL THERAPY; BK VIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT REJECTION; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; NUCLEIC ACID AMPLIFICATION; ORGAN TRANSPLANTATION; PLASMAPHERESIS; POLYOMAVIRUS INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SCREENING; URINE CYTOLOGY; VIRUS LOAD; VIRUS REPLICATION; EPIDEMIOLOGICAL MONITORING; EUROPE; GRAFT RECIPIENT; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; MASS SCREENING; POLYOMAVIRUS INFECTIONS; PROCEDURES;

EPIDEMIOLOGICAL MONITORING; EUROPE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFECTION CONTROL; MASS SCREENING; ORGAN TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; TRANSPLANT RECIPIENTS;

EID: 84908220252     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12538     Document Type: Review

References (154)

1. Rinaldo CH, Hirsch HH. The human polyomaviruses: from orphans and mutants to patchwork family. APMIS 2013; 121: 681-684.
2. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1: 1257-1260.
3. Hirsch HH, Kardas P, Kranz D, Leboeuf C. The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 2013; 121: 685-727.
4. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1: 1253-1257.
5. Rinaldo CH, Tylden GD, Sharma BN. The human polyomavirus BK (BKPyV): virological background and clinical implications. APMIS 2013; 121: 728-745.
6. Babakir-Mina M, Ciccozzi M, Perno CF, Ciotti M. The human polyomaviruses KI and WU: virological background and clinical implications. APMIS 2013; 121: 746-754.
7. Coursaget P, Mahtab S, Nicol JTJ, Gardair C, Touzé A. Human Merkel cell polyomavirus: virological background and clinical implications. APMIS 2013; 121: 755-769.
8. Kazem S, van der Meijden E, Feltkamp MC. The trichodysplasia spinulosa-associated polyomavirus; virological background and clinical implications. APMIS 2013; 121: 770-782.
9. Ehlers B, Wieland U. The novel human polyomaviruses HPyV6, 7, 9 and beyond. APMIS 2013; 121: 783-795.
10. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5: e1000363.
11. Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837-846.
12. Bofill-Mas S, Rodriguez-Manzano J, Calgua B, Carratala A, Girones R. Newly described human polyomaviruses Merkel cell, KI and WU are present in urban sewage and may represent potential environmental contaminants. Virol J 2010; 7: 141.
13. Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J Virol 2001; 75: 10290-10299.
14. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-854.
15. Hirsch HH, Randhawa P. BK Polyomavirus in Solid Organ Transplantation. Am J Transplant 2013; 13(suppl 4): 179-188.
16. KDIGO. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (suppl 3): S1-155.
17. Caliendo AM. Editorial commentary: the long road toward standardization of viral load testing for cytomegalovirus. Clin Infect Dis 2013; 56: 374-375.
18. Caliendo AM, Ingersoll J, Fox-Canale AM et al. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J Clin Microbiol 2007; 45: 1723-1727.
19. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277-1286.
20. Hayden RT, Yan X, Wick MT et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol 2012; 50: 337-345.
21. Drachenberg CB, Hirsch HH, Papadimitriou JC et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 2007; 84: 323-330.
22. Singh HK, Bubendorf L, Mihatsch MJ, Drachenberg CB, Nickeleit V. Urine cytology findings of polyomavirus infections. Adv Exp Med Biol 2006; 577: 201-212.
23. Singh HK, Donna Thompson B, Nickeleit V. Viral Haufen are urinary biomarkers of polyomavirus nephropathy: new diagnostic strategies utilizing negative staining electron microscopy. Ultrastruct Pathol 2009; 33: 222-235.
24. Hirsch HH, Knowles W, Dickenmann M et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488-496.
25. Ginevri F, De Santis R, Comoli P et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003; 75: 1266-1270.
26. Bohl DL, Brennan DC, Ryschkewitsch C, Gaudreault-Keener M, Major EO, Storch GA. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008; 43: 184-189.
27. Bijol V, Cimic A, Viscidi RP, Hymes LC. Pretransplant IgG antibodies to polyoma BK virus in pediatric renal transplants. Pediatr Transplant 2010; 14: 224-227.
28. Sood P, Senanayake S, Sujeet K et al. Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: a prospective single-center study. Transplantation 2013; 95: 896-902.
29. Pastrana DV, Brennan DC, Cuburu N et al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog 2012; 8: e1002650.
30. Ginevri F, Pastorino N, de Santis R et al. Retransplantation after kidney graft loss due to polyoma BK virus nephropathy: successful outcome without original allograft nephrectomy. Am J Kidney Dis 2003; 42: 821-825.
31. Krymskaya L, Sharma MC, Martinez J et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 2005; 79: 11170-11178.
32. Randhawa PS, Popescu I, Macedo C et al. Detection of CD8 + T cells sensitized to BK virus large T antigen in healthy volunteers and kidney transplant recipients. Hum Immunol 2006; 67: 298-302.
33. Binggeli S, Egli A, Schaub S et al. Polyomavirus BK-Specific Cellular Immune Response to VP1 and Large T-Antigen in Kidney Transplant Recipients. Am J Transplant 2007; 7: 1131-1139.
34. Ginevri F, Basso S, Hirsch HH et al. Reconstitution of BKV-specific immunity through immunosuppression reduction prevents BKV nephropathy in pediatric kidney recipients monitored prospectively. Transpl Int 2007; 20(suppl 2): 80.
35. Chen Y, Trofe J, Gordon J, Autissier P, Woodle ES, Koralnik IJ. BKV and JCV large T antigen-specific CD8(+) T cell response in HLA A*0201(+) kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol 2008; 42: 198-202.
36. Egli A, Kohli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation 2009; 88: 1161-1168.
37. Schachtner T, Muller K, Stein M et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 2011; 11: 2443-2452.
38. Balduzzi A, Lucchini G, Hirsch HH et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2011; 46: 987-992.
39. Lima MA, Marzocchetti A, Autissier P et al. Frequency and phenotype of JC virus-specific CD8 + T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 2007; 81: 3361-3368.
40. Gheuens S, Bord E, Kesari S et al. Role of CD4 + and CD8 + T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 2011; 85: 7256-7263.
41. Jilek S, Jaquiery E, Hirsch HH et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010; 9: 264-272.
42. Khanna N, Wolbers M, Mueller NJ et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 2009; 83: 4404-4411.
43. Kumar A, Kantele A, Jarvinen T et al. Trichodysplasia spinulosa-associated polyomavirus (TSV) and Merkel cell polyomavirus: correlation between humoral and cellular immunity stronger with TSV. PLoS ONE 2012; 7: e45773.
44. Iyer JG, Afanasiev OK, McClurkan C et al. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 2011; 17: 6671-6680.
45. Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
46. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13(suppl 4): 93-106.
47. Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hariharan S. Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation 2008; 85: 185-192.
48. Randhawa PS, Finkelstein S, Scantlebury V et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67: 103-109.
49. Binet I, Nickeleit V, Hirsch HH et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999; 67: 918-922.
50. Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582-594.
51. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019-1026.
52. Schold JD, Rehman S, Kayler LK, Magliocca J, Srinivas TR, Meier-Kriesche HU. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22: 626-634.
53. Hirsch HH, Vincenti F, Friman S et al. Polyomavirus BK Replication in De Novo Kidney Transplant Patients Receiving Tacrolimus or Cyclosporine: a Prospective, Randomized, Multicenter Study. Am J Transplant 2013; 13: 136-145.
54. Borni-Duval C, Caillard S, Olagne J et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation 2013; 95: 1498-1505.
55. Kazory A, Ducloux D, Chalopin JM, Angonin R, Fontaniere B, Moret H. The first case of JC virus allograft nephropathy. Transplantation 2003; 76: 1653-1655.
56. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005; 17: 658-665.
57. Mateen FJ, Muralidharan R, Carone M et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70: 305-322.
58. Khanna N, Elzi L, Mueller NJ et al., for the Swiss HIV Cohort Study. Incidence and Outcome of Progressive Multifocal Leukoencephalopathy in 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48: 1459-1466.
59. Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
60. Nickeleit V, Klimkait T, Binet IF et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309-1315.
61. Hirsch HH, Meylan PR, Zimmerli W, Iten A, Battegay M, Erb P. HIV-1-infected patients with focal neurologic signs: diagnostic role of PCR for Toxoplasma gondii, Epstein-Barr virus, and JC virus. Clin Microbiol Infect 1998; 4: 577-584.
62. Viscidi RP, Khanna N, Tan CS et al. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011; 53: 711-715.
63. Caccetta TP, Dessauvagie B, McCallum D, Kumarasinghe SP. Multiple minute digitate hyperkeratosis: a proposed algorithm for the digitate keratoses. J Am Acad Dermatol 2012; 67: e49-e55.
64. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005; 89: 1-4.
65. Heath M, Jaimes N, Lemos B et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008; 58: 375-381.
66. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-1100.
67. Shuda M, Feng H, Kwun HJ et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A 2008; 105: 16272-16277.
68. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest 2011; 121: 3623-3624.
69. Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. Virology 2013; 437: 63-72.
70. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog 2009; 5: e1000578.
71. Pastrana DV, Wieland U, Silling S, Buck CB, Pfister H. Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer. Med Microbiol Immunol 2012; 201: 17-23.
72. Touze A, Le Bidre E, Laude H et al. High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. J Clin Oncol 2011; 29: 1612-1619.
73. Astegiano S, Bergallo M, Solidoro P et al. Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients. Transplant Proc 2010; 42: 1275-1278.
74. Bergallo M, Costa C, Terlizzi ME et al. Quantitative detection of the new polyomaviruses KI, WU and Merkel cell virus in transbronchial biopsies from lung transplant recipients. J Clin Pathol 2010; 63: 722-725.
75. Kuypers J, Campbell AP, Guthrie KA et al. WU and KI Polyomaviruses in Respiratory Samples from Allogeneic Hematopoietic Cell Transplant Recipients. Emerg Infect Dis 2012; 18: 1580-1588.
76. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus. Clin Infect Dis 2013; 56: 258-266.
77. Scuda N, Hofmann J, Calvignac-Spencer S et al. A novel human polyomavirus closely related to the african green monkey-derived lymphotropic polyomavirus. J Virol 2011; 85: 4586-4590.
78. Almeras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis 2011; 13: 101-108.
79. Viscount HB, Eid AJ, Espy MJ et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 2007; 84: 340-345.
80. Gosert R, Rinaldo CH, Funk GA et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008; 205: 841-852.
81. Drachenberg CB, Papadimitriou JC, Hirsch HH et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004; 4: 2082-2092.
82. Vats A, Shapiro R, Singh RP et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003; 75: 105-112.
83. Dumoulin A, Hirsch HH. Reevaluating and optimizing polyomavirus BK and JC real-time PCR assays to detect rare sequence polymorphisms. J Clin Microbiol 2011; 49: 1382-1388.
84. Randhawa P, Kant J, Shapiro R, Tan H, Basu A, Luo C. Impact of genomic sequence variability on quantitative PCR assays for diagnosis of polyomavirus BK infection. J Clin Microbiol 2011; 49: 4072-4076.
85. Dadhania D, Snopkowski C, Ding R et al. Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation 2010; 90: 189-197.
86. Singh HK, Andreoni KA, Madden V et al. Presence of urinary haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol 2009; 20: 416-427.
87. Wojciechowski D, Chanda R, Chandran S et al. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation 2012; 94: 1117-1123.
88. Humar A, Gill J, Johnston O et al. Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial. Trials 2013; 14: 185.
89. Gabardi S, Waikar SS, Martin S et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 2010; 5: 1298-1304.
90. Wali RK, Drachenberg C, Hirsch HH et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004; 78: 1069-1073.
91. Isakova T, Xie H, Messinger S et al. Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation. Am J Transplant 2013; 13: 100-110.
92. Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation 2010; 89: 1462-1465.
93. Randhawa P, Bohl D, Brennan D et al. Longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients. Clin Vaccine Immunol 2008; 15: 1564-1571.
94. Bodaghi S, Comoli P, Boesch R et al. Antibody responses to recombinant polyomavirus BK large T and VP1 proteins in pediatric kidney transplant patients. J Clin Micro 2009; 47: 2577-2585.
95. Hariharan S, Cohen EP, Vasudev B et al. BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis. Am J Transplant 2005; 5: 2719-2724.
96. Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant 2009; 13: 123-129.
97. Sener A, House AA, Jevnikar AM et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006; 81: 117-120.
98. Ginevri F, Azzi A, Hirsch HH et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727-2735.
99. Schaub S, Hirsch HH, Dickenmann M et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010; 10: 2615-2623.
100. Sood P, Senanayake S, Sujeet K et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation 2012; 94: 814-821.
101. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-Virus and the Impact of Pre-Emptive Immunosuppression Reduction: 5-Year Results. Am J Transplant 2010; 2010: 5.
102. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010; 89: 1057-1070.
103. Schwarz A, Linnenweber-Held S, Heim A et al. Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation. Transplantation 2012; 94: 396-402.
104. Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res 2011; 92: 115-123.
105. Sar A, Worawichawong S, Benediktsson H, Zhang J, Yilmaz S, Trpkov K. Interobserver agreement for Polyomavirus nephropathy grading in renal allografts using the working proposal from the 10th Banff Conference on Allograft Pathology. Hum Pathol 2011; 42: 2018-2024.
106. Masutani K, Shapiro R, Basu A, Tan H, Wijkstrom M, Randhawa P. The Banff 2009 Working Proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome. Am J Transplant 2012; 12: 907-918.
107. Menter T, Mayr M, Schaub S, Mihatsch MJ, Hirsch HH, Hopfer H. Pathology of resolving polyomavirus-associated nephropathy. Am J Transplant 2013; 13: 1474-1483.
108. Dziubianau M, Hecht J, Kuchenbecker L et al. TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am J Transplant 2013; 13: 2842-2854.
109. Batal I, Franco ZM, Shapiro R et al. Clinicopathologic analysis of patients with BK viruria and rejection-like graft dysfunction. Hum Pathol 2009; 40: 1312-1319.
110. Batal I, Zainah H, Stockhausen S et al. The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy. Mod Pathol 2009; 4: 4.
111. Munoz P, Fogeda M, Bouza E, Verde E, Palomo J, Banares R. Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis 2005; 41: 1720-1725.
112. Egli A, Helmersen DS, Taub K, Hirsch HH, Johnson A. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant 2010; 10: 2324-2330.
113. Loeches B, Valerio M, Palomo J, Bouza E, Munoz P. BK virus in heart transplant recipients: a prospective study. J Heart Lung Transplant 2011; 30: 109-111.
114. Doucette KE, Pang XL, Jackson K et al. Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation 2008; 85: 1733-1736.
115. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis 2005; 192: 1349-1354.
116. Barton TD, Blumberg EA, Doyle A et al. A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction. Transpl Infect Dis 2006; 8: 102-107.
117. Barber CE, Hewlett TJ, Geldenhuys L, Kiberd BA, Acott PD, Hatchette TF. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transpl Infect Dis 2006; 8: 113-121.
118. Limaye AP, Smith KD, Cook L et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5: 614-620.
119. Menahem SA, McDougall KM, Thomson NM, Dowling JP. Native kidney BK nephropathy post cardiac transplantation. Transplantation 2005; 79: 259.
120. Sahney S, Yorgin P, Zuppan C, Cutler D, Kambham N, Chinnock R. BK virus nephropathy in the native kidneys of a pediatric heart transplant recipient. Pediatr Transplant 2010; 14: E11-E15.
121. Ali FN, Meehan SM, Pahl E, Cohn RA. Native BK viral nephropathy in a pediatric heart transplant recipient. Pediatr Transplant 2010; 14: E38-E41.
122. Masuda K, Akutagawa K, Yutani C, Kishita H, Ishibashi-Ueda H, Imakita M. Persistent infection with human polyomavirus revealed by urinary cytology in a patient with heart transplantation. A case report. Acta Cytol 1998; 42: 803-806.
123. Maddirala S, Pitha JV, Cowley BD Jr, Haragsim L. End-stage renal disease due to polyomavirus in a cardiac transplant patient. Nat Clin Pract Nephrol 2007; 3: 393-396.
124. Pendse SS, Vadivel N, Ramos E et al. BK viral reactivation in cardiac transplant patients: evidence for a double-hit hypothesis. J Heart Lung Transplant 2006; 25: 814-819.
125. Lorica C, Bueno TG, Garcia-Buitrago MT, Rusconi P, Gonzalez IA. BK virus nephropathy in a pediatric heart transplant recipient with post-transplant lymphoproliferative disorder: a case report and review of literature. Pediatr Transplant 2013; 17: E55-E61.
126. Butts RJ, Uber WE, Savage AJ. Treatment of BK viremia in a pediatric heart transplant recipient. J Heart Lung Transplant 2012; 31: 552-553.
127. Thomas LD, Vilchez RA, White ZS et al. A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis 2007; 195: 442-449.
128. Elidemir O, Chang IF, Schecter MG, Mallory GB. BK virus-associated hemorrhagic cystitis in a pediatric lung transplant recipient. Pediatr Transplant 2007; 11: 807-810.
129. Schwarz A, Mengel M, Haller H, Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant 2005; 5: 2582-5285.
130. Sharma SG, Nickeleit V, Herlitz LC et al. BK polyoma virus nephropathy in the native kidney. Nephrol Dial Transplant 2013; 28: 620-631.
131. Dufek S, Haitel A, Muller-Sacherer T, Aufricht C. Duct Bellini carcinoma in association with BK virus nephropathy after lung transplantation. J Heart Lung Transplant 2013; 32: 378-379.
132. Loeches B, Valerio M, Perez M et al. BK virus in liver transplant recipients: a prospective study. Transplant Proc 2009; 41: 1033-1037.
133. Splendiani G, Cipriani S, Condo S et al. Polyoma virus BK and renal dysfunction in a transplanted population. Transplant Proc 2004; 36: 713-715.
134. Randhawa P, Uhrmacher J, Pasculle W et al. A comparative study of BK and JC virus infections in organ transplant recipients. J Med Virol 2005; 77: 238-243.
135. Puliyanda DP, Amet N, Dhawan A et al. Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy. Clin Transplant 2006; 20: 289-294.
136. Yousry TA, Pelletier D, Cadavid D et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72: 779-787.
137. Gheuens S, Wuthrich C, Koralnik IJ. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 2013; 8: 189-215.
138. Ferenczy MW, Marshall LJ, Nelson CD et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012; 25: 471-506.
139. Crowder CD, Gyure KA, Drachenberg CB et al. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant 2005; 5: 1151-1158.
140. Vulliemoz S, Lurati-Ruiz F, Borruat FX et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 2006; 77: 1079-1082.
141. Park JH, Ryoo S, Noh HJ et al. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep Neurol 2011; 3: 258-262.
142. Lanzafame M, Ferrari S, Lattuada E et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med 2009; 17: 35-37.
143. Clifford DB, Nath A, Cinque P et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 2013; 19: 351-358.
144. Hall CD, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338: 1345-1351.
145. Kraemer C, Evers S, Nolting T, Arendt G, Husstedt IW. Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy. J Neurol 2008; 255: 526-531.
146. De Luca A, Ammassari A, Pezzotti P et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22: 1759-1767.
147. European Medicines Agency. Scientific Discussion. 2005 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussion/human/000121/WC500052069.pdf.
148. VISTIDE (cidofovir injection) Rx only. HUMAN PRESCRIPTION DRUG LABEL. dailymed.nlm.nih.gov/dailymed/lookup.cfm: Gilead Sciences, Inc.; 2010.
149. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36: 127-143.
150. Gosert R, Rinaldo CH, Wernli M, Major EO, Hirsch HH. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob Agents Chemother 2011; 55: 2129-2136.
151. Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369: 1227-1236.
152. Senchenkov A, Moran SL. Merkel cell carcinoma: diagnosis, management, and outcomes. Plast Reconstr Surg 2013; 131: 771e-778e.
153. Siva S, Byrne K, Seel M et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of merkel cell carcinoma: a 15-year institutional experience. J Nucl Med 2013; 54: 1223-1229.
154. Farasat S, Yu SS, Neel VA et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011; 64: 1051-1059.